American Society of Clinical Oncology
225 Reinekers Lane
2088 articles about American Society of Clinical Oncology
The College of American Pathologists and American Society of Clinical Oncology have reaffirmed the Human Epidermal Growth Factor Receptor 2 Breast Cancer Testing Guidelines, reducing confusion over terminology for reporting HER2 results.
Genomic Testing Cooperative Presents at ASCO meeting Studies Demonstrating the Power of its Liquid Biopsy and Tissue-Based Targeted Transcriptomic Approach when Combined with Artificial Intelligence
Genomic Testing Cooperative, LCA announced that it will be presenting at the 2023 American Society of Clinical Oncology Annual Meeting three studies illustrating the power of its proprietary RNA next generation sequencing approach in advancing liquid biopsy and tissue-based precision testing.
Well-known for its neurological drug development programs, Alkermes has firmly planted its flag as an oncology company at ASCO. Alkermes Head of Oncology Jessicca Rege spoke with BioSpace.
Primary seven-year data from Janssen's (Johnson & Johnson) Phase III trial of Imbruvica (ibrutinib) in lymphoma demonstrated positive survival outcomes.
Gilead Sciences shared what seemed to be good news regarding Trodelvy in HR+/HER2- breast cancer at the 2022 American Society of Clinical Oncology's annual meeting.
Data presented at the ASCO meeting this weekend show that treatment with Enhertu demonstrated a 49% improvement in median overall survival by more than six months.
Four life sciences companies posted previews of their respective programs ahead of the American Society of Clinical Oncology (ASCO) annual meeting on June 5, 2022.
Zymeworks increased its stake in the company to 6.9%, slightly under 4 million shares, and options with shares popped 13% after the original bid and are up another 10%.
New Data Showcases How Amgen Is Advancing All Angles of Cancer Care Through Innovative Oncology Portfolio and Pipeline at ASCO 2022
Amgen will present new data from across its broad oncology innovative medicines and biosimilars portfolio and robust pipeline at the American Society of Clinical Oncology Annual Meeting from June 3-7 in Chicago and virtually.
The American Society of Clinical Oncology and the Association of Community Cancer Centers are combining their efforts to increase racial and ethnic diversity in clinical trials.
Janssen Data at ASCO GU Demonstrate Longstanding Leadership in Prostate Cancer and Commitment to Advancing Potential New Therapeutic Options for Genitourinary Cancers
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that 17 presentations will be featured at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium, taking place in San Francisco and virtually from February 17-19.
Alkermes to Present Data on Nemvaleukin Alfa at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium
Alkermes plc announced plans to present a poster related to nemvaleukin alfa, the company's novel, investigational, engineered interleukin-2 variant immunotherapy, at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium, taking place Jan. 20-22, 2022.
In an interview with BioSpace, CEO Victoria Richon expressed her excitement about investor support and developing novel, first-in-class treatments.
The FDA granted it to Lu-PSMA-617, an investigational radioligand therapy to treat metastatic castration-resistant prostate cancer.
Novartis flexed its clinical muscles over the weekend, announcing results from multiple studies including different types of cancer and kidney disease.
Heat Biologics to Showcase Favorable Survival Data of HS-110 in Previously Treated Non-Small Cell Lung Cancer Patients at 2021 American Society of Clinical Oncology Annual Meeting
Survival benefit observed in two treatment settings of previously treated non-small lung cancer patients
With the 2021 American Society of Clinical Oncology Annual Meeting now in high gear, there is plenty of news. Here’s a look at just some of the most recent stories.
ImmVira will present the U.S. Clinical Phase I Study Results of MVR-T3011 via Intratumoral Administration at ASCO 2021
ImmVira will present results from its clinical Phase I study of MVR-T3011 via intratumoral administration at the 2021 American Society of Clinical Oncology Annual Meeting on June 4-8, 2021 for the first time.
Lilly Announces Details of Presentations at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
New data from across Eli Lilly and Company's oncology portfolio will be presented at the 2021 American Society of Clinical Oncology Annual Meeting, held June 4-8, 2021.
Two Complete Responses and Response Rate of 41% for People with Synovial Sarcoma Reported at ASCO in Adaptimmune’s Phase 2 SPEARHEAD-1 Trial
Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, will report initial data from its Phase 2 SPEARHEAD-1 trial, with afamitresgene autoleucel, at the American Society of Clinical Oncology congress.